Thomas C Witt
Overview
Explore the profile of Thomas C Witt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Budnick H, Schneider D, Zauber S, Witt T, Gupta K
World Neurosurg
. 2023 Oct;
181:e346-e355.
PMID: 37839566
Background: Deep brain stimulation of the subthalamic nucleus (STN-DBS) for Parkinson's disease can be performed with intraoperative neurophysiological and radiographic guidance. Conventional T2-weighted magnetic resonance imaging sequences, however, often fail...
2.
Patel R, Zauber S, Yadav A, Witt T, Halum S, Gupta K
Neurosurgery
. 2022 Feb;
90(4):457-463.
PMID: 35138294
Background: Adductor laryngeal dystonia (ADLD) is a substantially debilitating focal progressive neurological voice disorder. Current standard of care is symptomatic treatment with repeated injections of botulinum toxin into specific intrinsic...
3.
Nair D, Laxer K, Weber P, Murro A, Park Y, Barkley G, et al.
Neurology
. 2020 Jul;
95(9):e1244-e1256.
PMID: 32690786
Objective: To prospectively evaluate safety and efficacy of brain-responsive neurostimulation in adults with medically intractable focal onset seizures (FOS) over 9 years. Methods: Adults treated with brain-responsive neurostimulation in 2-year...
4.
Hirsch L, Mirro E, Salanova V, Witt T, Drees C, Brown M, et al.
Epilepsia
. 2020 Feb;
61(3):408-420.
PMID: 32072621
Objective: To describe seizure outcomes in patients with medically refractory epilepsy who had evidence of bilateral mesial temporal lobe (MTL) seizure onsets and underwent MTL resection based on chronic ambulatory...
5.
Vale F, Bozorg A, Schoenberg M, Wong K, Witt T
J Neurosurg
. 2012 Jul;
117(5):962-9.
PMID: 22839651
Epilepsy surgery is an effective treatment for medically resistant temporal lobe epilepsy (TLE). To minimize complication rates and potentially improve neuropsychology outcomes, stereotactic radiosurgery (SRS) has been explored as an...
6.
Henderson M, Fakiris A, Timmerman R, Worth R, Lo S, Witt T
Stereotact Funct Neurosurg
. 2009 Mar;
87(3):161-7.
PMID: 19321969
Patients with low-grade astrocytoma (LGA; 8 pilocytic astrocytomas, 2 subependymal giant cell astrocytomas, 2 fibrillary astrocytomas) were selected for treatment with gamma knife stereotactic radiosurgery (GKSRS) based on having a...
7.
Barbaro N, Quigg M, Broshek D, Ward M, Lamborn K, Laxer K, et al.
Ann Neurol
. 2009 Feb;
65(2):167-75.
PMID: 19243009
Objective: The safety, efficacy, and morbidity of radiosurgery (RS) must be established before it can be offered as an alternative to open surgery for unilateral mesial temporal lobe epilepsy. We...
8.
Endocrine response after gamma knife-based stereotactic radiosurgery for secretory pituitary adenoma
Tinnel B, Henderson M, Witt T, Fakiris A, Worth R, Des Rosiers P, et al.
Stereotact Funct Neurosurg
. 2008 Sep;
86(5):292-6.
PMID: 18758206
Purpose: To examine treatment outcomes of Gamma Knife-based stereotactic radiosurgery (GK-based SRS) for secretory pituitary adenomas. Materials And Methods: 25 patients were treated with GK-based SRS for secretory pituitary adenomas...
9.
Witt T, Lo S, Timmerman R
Stereotact Funct Neurosurg
. 2007 Aug;
85(6):310-3.
PMID: 17709987
Most childhood rhabdoid tumors occur in the kidney or central nervous system but they can occur in other sites and they usually run an aggressive clinical course. We report a...
10.
Fakiris A, Lo S, Henderson M, Witt T, Worth R, Danis R, et al.
Stereotact Funct Neurosurg
. 2007 Jan;
85(2-3):106-12.
PMID: 17228176
Nineteen patients with uveal melanoma were treated with Gamma-Knife-based stereotactic radiosurgery (SRS). The radiation dose was 40 Gy prescribed to the 50% isodose line for all patients. The median follow-up...